Home Business Biotech could lead on subsequent leg, Oppenheimer analyst says

Biotech could lead on subsequent leg, Oppenheimer analyst says

3 min read
0
0
30

Because the Nasdaq hits information, one analyst is betting on a nook of the health-care sector nonetheless properly offs its highs to drive the subsequent leg of the rally.

“The Nasdaq Composite broadly is breaking larger, and the important thing motive why is that it isn’t simply tech anymore. You have got biotechnology additionally lifting its head larger and taking part,” Ari Wald, head of technical evaluation at Oppenheimer, informed CNBC’s “Buying and selling Nation” on Monday.

The IBB biotechnology ETF, which holds shares comparable to Biogen and Amgen, has risen 6% this month. That is roughly double the beneficial properties on the broader Nasdaq. Nonetheless, it’s nonetheless 7% from its February excessive.

“Speaking in regards to the power within the Nasdaq Biotech ETF, … it actually began with the breakout by way of five-year resistance final 12 months,” he mentioned.

He added that this upturn following a consolidation appears just like how the ETF traded final summer time. Like this 12 months, the IBB consolidated for 5 months after which broke larger. Wald mentioned each of these bullish tendencies bode properly for extra upside.

Nancy Tengler, chief funding officer at Laffer Tengler Investments, prefers to be selective inside the biotech house.

“We’re enjoying the house with particular person holdings. Our two largest are J&J, which by the best way purchased Actelion which is without doubt one of the largest biotech firms, and AbbVie, which is alternately characterised as pharma and biotech,” mentioned Tengler.

Johnson & Johnson and AbbVie have had a combined month, falling 2% and gaining 2%, respectively.

Disclosure: Laffer Tengler Investments holds ABBV and JNJ.

Disclaimer


Supply hyperlink

Load More Related Articles
Load More By The Texas Chronicle
Load More In Business

Leave a Reply

Your email address will not be published. Required fields are marked *

Check Also

Despite hybrid release, ‘Dune’ draws well on the big screen

Denis Villeneuve’s “Dune” debuted with $40.1 million in ticket sales in …